Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

60.63USD
16 Feb 2018
Change (% chg)

$1.13 (+1.90%)
Prev Close
$59.50
Open
$59.27
Day's High
$60.90
Day's Low
$59.27
Volume
36,106
Avg. Vol
29,408
52-wk High
$68.57
52-wk Low
$41.64

Chart for

About

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $888.94
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology

* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Anika Therapeutics Expands Strategic Collaboration With Institute For Applied Life Sciences

* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:

Jan 24 2018

BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment

* ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT

Dec 27 2017

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

Oct 25 2017

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

Oct 16 2017

Competitors

Earnings vs. Estimates